A Phase 1/2 interventional study of ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T in Inflammatory Bowel Diseases (IBD), sponsored by iCell Gene Therapeutics. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by iCell Gene Therapeutics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Inflammatory Bowel Diseases with a site in China — 49 open to participants now, 53 under way, 5 of them phase 3. Inflammatory Bowel Diseases · China.
Among the 112 studies in Inflammatory Bowel Diseases with a site in China, this one is the 56th largest by planned enrollment of the 58 interventional ones that give a count, is one of 9 that started in 2026, is the only one in phase 1/2, reaches primary completion later than 43 of the 52 other live ones, and was the 103rd registered.
1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 424 are open to participants now.
Browse Inflammatory Bowel Diseases studies →49 of the 112 studies in Inflammatory Bowel Diseases with a site in China are open now. Recruiting first, the newest first:
Benethera (Shaoxing) Biotechnology Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
First Affiliated Hospital of Kunming Medical University · Sites in China
Ages 18–60
Changhai Hospital · Sites in China
Ages 18–75
InSilico Medicine Hong Kong Limited · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 12 · Phase 3 9
First in 2009; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 68 across 870 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 97 across the 58 interventional studies, 148 across the 54 observational. Of the 35 that completed or were terminated, 6 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 112 have an industry lead sponsor. The 10 most frequent:
iCell Gene Therapeutics is the lead sponsor of 17 studies on the registry; 7 are open to participants now.
iCell Gene Therapeutics has 1 study filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
12 of the studies in Inflammatory Bowel Diseases with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06713694Wang ZhenThe Impact of Culture in Cognitive Behavior Therapy (CBT) for Patients With Inflammatory Bowel Disease | 2026-12-30 |
| NCT07632573Benethera (Shaoxing) Biotechnology Co., Ltd.A Phase I Study to Evaluate the Safety/Tolerability of BDHK-2009 Tablets in Healthy Adult | 2026-12-31 |
| NCT07165470Changhai HospitalPre-Packaged Low-Residue Diet Assisting Bowel Preparation in Patients With Inflammatory Bowel Disease | 2026-12-31 |
| NCT06483373Shanghai Pharmaceuticals Holding Co., LtdA Clinical Study of SPH7854 Granules in Healthy Subjects. | 2026-12-31 |
| NCT04187820Shanghai Institute of Acupuncture, Moxibustion and MeridianEffect of Acupuncture on Mild to Moderate Active Crohn's Disease | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 112 studies in Inflammatory Bowel Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with relapsed and/or refractory inflammatory bowel disease.
Inflammatory bowel disease (IBD) is a chronic, immune-mediated disease of the gastrointestinal (GI) tract. IBD may result in GI lesions as well as extraintestinal manifestations affecting the joints, skin, eyes, and biliary system. IBD is driven by humoral immune cells including B cells, plasma cells and long-lived plasma cells.
ICG318 CAR-T, the investigational agent in this clinical trial, is an armored, compound chimeric antigen receptor (cCAR) composed of two independently functioning CARs that target the CD19 surface antigen and the BCMA surface antigen on B cells and plasma/long-lived plasma cells, respectively.
This study is being conducted to evaluate the safety and efficacy of ICG318 CAR-T in patients with refractory IBD. A single dose of ICG318 CAR-T will be evaluated after cyclophosphamide and fludarabine lymphodepletion.
Key Inclusion criteria:
Key Exclusion criteria:
11) central nervous system disease determined by the investigator to impair the subjects ability to participate safely in this trial.
12) Subjects with prior or concurrent . Exceptions may be determined at the discretion of the investigator.
13) Vaccination within 30 days before screening and vaccination within 3 months after planned cell ICG318 CAR-T infusion.
14) Subjects who are receiving or have received another drug or drugs without adequate time as determined by the principal investigator.
15) Those who are judged by the investigator to be unfit for leukapheresis, or whose IBD disease severity and trajectory are not compatible with infusion with ICG318 CAR-T cells, or any critical steps of the trial evaluation such as but not limited to to colonoscopy.
16) Female subjects who are pregnant or lactating. 17) diseases judged by the investigator to require systemic treatment and affect the evaluation of efficacy.
18) Suicidal tendencies, tobacco use, substance use, or alcohol abuse as determined by the investigator.
19) Those who have a history of a severe drug allergy, or are allergic to the test drug ingredients, or combined therapeutic drugs.
20) Other conditions that the investigator believes should not participate in this clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T
Anti-BCMA, Anti-CD19 Compound CAR-T cells
Number of Adverse Events (AEs) after ICG318 CAR-T infusion.
Number of participants with AEs, Serious Adverse Events (SAEs), Treatment Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESI), and Dose Limiting Toxicities (DLTs).
Time frame: Starting day 0 and up to 2 years after ICG318 CAR-T infusion.
Determine the recommended phase 2 dose (RP2D) regimen.
The protocol is based on cohort schema with dose escalation from 1×10\^6/kg to 4×10\^6/kg.
Time frame: Starting day 0 and assessed 2 years after ICG318 CAR-T infusion.
The proportion of subjects who achieved drug-free remission.
Clinical, endoscopic, and histological remission maintained without any IBD-directed therapy.
Time frame: At 6 months, 12 months, 24 months after ICG318 CAR-T infusion.
Fecal calprotectin levels.
Time frame: 28 days, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months after ICG318 CAR-T infusion.
Cmax
Maximum serum concentration of ICG318 CAR-T.
Time frame: Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.
Tmax
Time to maximum serum concentration of ICG318 CAR-T.
Time frame: Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.
T1/2
Half-life of ICG318 CAR-T serum concentration.
Time frame: Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.
AUC
Plasma ICG318 CAR-T concentration versus time. Total systemic exposure to ICG318 CAR-T over time.
Time frame: Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.
Rate of B cell elimination and naïve B-Cell recovery
B cell subsets will be assessed by flow cytometry panels and B-Cell receptor sequencing.
Time frame: Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.
Recovery of immunoglobulins
Immunoglobulins IgG, IgM and IgA levels.
Time frame: Assessed as per schedule of events up to 2 years after ICG318 CAR-T infusion.
The proportion of subjects who achieved clinical remission from Crohn's Disease (CD)
CD activity index (CDAI) remission
Time frame: 3 months, 6 months, 12 months, 18 months, 24 months after ICG318 CAR-T infusion.
The proportion of subjects who achieved clinical response from CD
CDAI reduction
Time frame: 3 months, 6 months, 12 months, 18 months, 24 months after ICG318 CAR-T infusion.
The proportion of subjects who achieved endoscopic remission from CD
SES-CD remission.
Time frame: 12 months, 24 months after ICG318 CAR-T.
The proportion of subjects who achieved endoscopic response from CD
SES-CD reduction
Time frame: 12 months, 24 months after ICG318 CAR-T.
Histological Remission from CD
Absence of inflammation on tissue samples collected from endoscopic biopsy.
Time frame: 12 months, 24 months after ICG318 CAR-T.
The proportion of subjects who achieved clinical remission from Ulcerative Colitis (UC)
Adapted Mayo score remission.
Time frame: 3 months, 6 months, 12 months, 18 months, 24 months after ICG318 CAR-T infusion.
The proportion of subjects who achieved clinical response from UC
Adapted Mayo score response.
Time frame: 3 months, 6 months, 12 months, 18 months, 24 months after ICG318 CAR-T infusion.
The proportion of subjects who achieved endoscopic remission from UC
Mayo Endoscopic Subscore (MES) remission.
Time frame: 12 months, 24 months after ICG318 CAR-T infusion.
The proportion of subjects who achieved endoscopic response from UC
MES response.
Time frame: 12 months, 24 months after ICG318 CAR-T infusion.
Histological remission from UC
Nancy Histological Index (NHI) scoring. Evaluation performed on tissue samples collected from endoscopic biopsy.
Time frame: 12 months, 24 months after ICG318 CAR-T infusion.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Apr 2028, 24 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
iCell Gene Therapeutics